An Open-Label Study of Vascazen in Cardiac Rehab Patients With Deficient Blood Omega-3 Fatty Acid Levels (CARE)

New York Hospital Queens

Status and phase

Unknown

Phase 2

Conditions

Dyslipidemia

Treatments

Other: VASCAZEN

Study type

Interventional

Funder types

Other

Identifiers

NCT02052986

VCT-01

Details and patient eligibility

About

The investigators aim to test the hypothesis that dietary supplementation with VASCAZEN will correct omega-3 deficiency in cardiac rehab patients and improve biochemical risk factors.

Enrollment

100 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Adult subjects (> or = 18 years of age)
Enrolled in Cardiac Rehabilitation clinic with documented cardiovascular disease as assessed by the principle investigator
Has had cardiovascular examination within the past 2 months

Exclusion criteria

Subjects who refuse to provide written consent
Subjects with medical conditions, as determined by the principal investigator, which prevented them from study participation
Subjects with a known bleeding or clotting disorder
Subjects with known allergies to fish
Subjects with an implantable cardiac defibrillator
Subjects with a heart transplant
Female subjects who are currently taking hormone replacement therapy
Subjects who are pregnant or planning on becoming pregnant
Subjects currently taking Omega-3 fatty acid supplements (either under medical supervision or self-administered)